Cargando…
Managing Stroke Prevention in Hypertrophic Obstructive Cardiomyopathy (HOCM) Patients Without Confirmed Persistent Atrial Fibrillation: A Dilemma of Anticoagulation
Hypertrophic obstructive cardiomyopathy (HOCM) is a genetic cardiovascular disorder characterized by the thickening of the heart muscle, particularly the left ventricle. It is a leading cause of sudden cardiac death in young individuals. HOCM is associated with various complications, including arrhy...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10561532/ https://www.ncbi.nlm.nih.gov/pubmed/37818120 http://dx.doi.org/10.7759/cureus.46612 |
_version_ | 1785117944694439936 |
---|---|
author | Henen, Christine Johnson, Elise A Sokol, Sergio |
author_facet | Henen, Christine Johnson, Elise A Sokol, Sergio |
author_sort | Henen, Christine |
collection | PubMed |
description | Hypertrophic obstructive cardiomyopathy (HOCM) is a genetic cardiovascular disorder characterized by the thickening of the heart muscle, particularly the left ventricle. It is a leading cause of sudden cardiac death in young individuals. HOCM is associated with various complications, including arrhythmias and an increased risk of stroke. Patients with HOCM are at an increased risk of stroke due to the development of atrial fibrillation (AFib), a common arrhythmia observed in HOCM. AFib can result in the formation of blood clots in the atria, which may subsequently embolize the brain, causing a stroke. However, not all HOCM patients develop persistent AFib, leading to uncertainty regarding the appropriate management of stroke prevention in these cases. This case study aims to explore the management of recurrent cerebrovascular events (CVA) in a patient with HOCM who does not have confirmed persistent AFib. The argument revolves around whether anticoagulation should be offered for secondary stroke prevention in HOCM patients without a confirmed diagnosis of persistent AFib. |
format | Online Article Text |
id | pubmed-10561532 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Cureus |
record_format | MEDLINE/PubMed |
spelling | pubmed-105615322023-10-10 Managing Stroke Prevention in Hypertrophic Obstructive Cardiomyopathy (HOCM) Patients Without Confirmed Persistent Atrial Fibrillation: A Dilemma of Anticoagulation Henen, Christine Johnson, Elise A Sokol, Sergio Cureus Cardiology Hypertrophic obstructive cardiomyopathy (HOCM) is a genetic cardiovascular disorder characterized by the thickening of the heart muscle, particularly the left ventricle. It is a leading cause of sudden cardiac death in young individuals. HOCM is associated with various complications, including arrhythmias and an increased risk of stroke. Patients with HOCM are at an increased risk of stroke due to the development of atrial fibrillation (AFib), a common arrhythmia observed in HOCM. AFib can result in the formation of blood clots in the atria, which may subsequently embolize the brain, causing a stroke. However, not all HOCM patients develop persistent AFib, leading to uncertainty regarding the appropriate management of stroke prevention in these cases. This case study aims to explore the management of recurrent cerebrovascular events (CVA) in a patient with HOCM who does not have confirmed persistent AFib. The argument revolves around whether anticoagulation should be offered for secondary stroke prevention in HOCM patients without a confirmed diagnosis of persistent AFib. Cureus 2023-10-07 /pmc/articles/PMC10561532/ /pubmed/37818120 http://dx.doi.org/10.7759/cureus.46612 Text en Copyright © 2023, Henen et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Cardiology Henen, Christine Johnson, Elise A Sokol, Sergio Managing Stroke Prevention in Hypertrophic Obstructive Cardiomyopathy (HOCM) Patients Without Confirmed Persistent Atrial Fibrillation: A Dilemma of Anticoagulation |
title | Managing Stroke Prevention in Hypertrophic Obstructive Cardiomyopathy (HOCM) Patients Without Confirmed Persistent Atrial Fibrillation: A Dilemma of Anticoagulation |
title_full | Managing Stroke Prevention in Hypertrophic Obstructive Cardiomyopathy (HOCM) Patients Without Confirmed Persistent Atrial Fibrillation: A Dilemma of Anticoagulation |
title_fullStr | Managing Stroke Prevention in Hypertrophic Obstructive Cardiomyopathy (HOCM) Patients Without Confirmed Persistent Atrial Fibrillation: A Dilemma of Anticoagulation |
title_full_unstemmed | Managing Stroke Prevention in Hypertrophic Obstructive Cardiomyopathy (HOCM) Patients Without Confirmed Persistent Atrial Fibrillation: A Dilemma of Anticoagulation |
title_short | Managing Stroke Prevention in Hypertrophic Obstructive Cardiomyopathy (HOCM) Patients Without Confirmed Persistent Atrial Fibrillation: A Dilemma of Anticoagulation |
title_sort | managing stroke prevention in hypertrophic obstructive cardiomyopathy (hocm) patients without confirmed persistent atrial fibrillation: a dilemma of anticoagulation |
topic | Cardiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10561532/ https://www.ncbi.nlm.nih.gov/pubmed/37818120 http://dx.doi.org/10.7759/cureus.46612 |
work_keys_str_mv | AT henenchristine managingstrokepreventioninhypertrophicobstructivecardiomyopathyhocmpatientswithoutconfirmedpersistentatrialfibrillationadilemmaofanticoagulation AT johnsonelisea managingstrokepreventioninhypertrophicobstructivecardiomyopathyhocmpatientswithoutconfirmedpersistentatrialfibrillationadilemmaofanticoagulation AT sokolsergio managingstrokepreventioninhypertrophicobstructivecardiomyopathyhocmpatientswithoutconfirmedpersistentatrialfibrillationadilemmaofanticoagulation |